The effect of ingaron on the dynamics of copies of deoxyribonucleic acid Epstein - Barr virus in saliva samples and on the manifestation of clinical


Cite item

Full Text

Abstract

A total of 60 patients (38 women and 22 men, 36,54±2,14 years old) with a Epstein - Barr infection were examined. The patients were divided into two groups depending on the treatment regimen: 1 group - 34 patients received ingaron therapy (10 intramuscular injections of 500000 units every other day); group 2-26 patients received valcyte (450 mg 2 times a day, by mouth, 2 months) + ingaron at the same dosage. One month after the end of antiviral therapy in the1st group, negative results of half-chain reaction were obtained only in 29,41% of patients. The combination of valcyte and ingaron in patients of the 2nd group was different and differed in the duration of the injection of ingarone: 2a group: ingaron10 injections of 500000 IU intramuscularly every other day; 2b group: ingaron 20 injections of 500000 IU intramuscularly every other day; 2c group: ingaron 10 injections of 500000 IU and 15 injections of 100000 IU intramuscularly every other day. The best result after the introduction of ingaron was obtained in 90% of patients who received the longest course of ingaron in the form of 20 injections of 500000 IU every other day in combination with valcyte. In the other groups, where the total dose of ingaron was lower, positive results were found in 60 and 66,7% of patients. A significant positive change in the number of copies of deoxyribonucleic acid Epstein - Barr virus was found in samples of saliva and the severity of clinical complaints in patients one month after the ingaron monotherapy or combination therapy (valcyte and ingaron) was completed. The best effect of treatment with ingaron is achieved in patients with chronic Epstein - Barr infection with the prolonged introduction of ingaron (at least 20 injections).

About the authors

I A Rakityanskaya

1Городская поликлиника № 112

Санкт-Петербург

T S Ryabova

1Городская поликлиника № 112; Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

U A Todzhibaev

1Городская поликлиника № 112

Санкт-Петербург

A A Kalashnikov

Всероссийский центр экстренной и радиационной медицины им. А.М. Никифорова

Санкт-Петербург

A S Manuilov

Военно-медицинская академия им. С.М. Кирова

Email: vmeda-nio@mil.ru
Санкт-Петербург

References

  1. Гайнанова, Е.Г. Клиническая эффективность цитокинотерапии гамма-интерфероном при варицелла-зостер герпес- вирусной инфекции / Е.Г. Гайнанова, В.Х. Фазылов, О.В. Скороходкина // Журн. инфектол. - 2010. - № 2 (4). - С. 56.
  2. Ершов, Ф.И. Гамма-Интерферон: новые возможности современной профилактики обострений простого герпеса / Ф.И. Ершов [и др.] // Росс. журн. кож. и венер. болезней. - 2009. - № 2. - С. 11-13.
  3. Казмирчук, В.Е. Клиника, диагностика и лечение герпес-вирусных инфекций человека / В.Е. Казмирчук, Д.В. Мальцев. - К., 2009. - 248 с.
  4. Хахалин, Л.Н. Ацикловир при лечении острых и рецидивирующих герпес-вирусных инфекций / Л.Н. Хахалин, Ф.И Абазова // Клин. фармакол. и терапия. - 1995. - № 4. - С. 78-81.
  5. Andersson, J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases / J. Andersson // J. Infect. Dis. Suppl. - 1996. - Vol. 100. - P. 72-82.
  6. Fagundes, C.P. Attachment anxiety is related to Epstein-Barr virus latency / C.P. Fagundes [et al.] // Brain Behav. Immun. - 2014. - Vol. 41. - P. 232-238.
  7. Fujisaki, T. Gamma-interferon for severe chronic active Epstein- Barr virus / T. Fujisaki, S. Nagafuchi, T. Okamura // Ann. Intern. Med. - 1993. - Vol. 118, № 6. - P. 474-475.
  8. Hellman, D. Chronic active Epstein-Barr virus infections in two immunodeficient patients / D. Hellman [et al.] // J. Pediatr. - 1983. - Vol. 103. - P. 585-588.
  9. Iwatsuki, K. The association of latent Epstein-Barr virus infection with hydroa vacciniforme / K. Iwatsuki [et al.] // Br. J. Dermatol. - 1999. - Vol. 140. - P. 715-721.
  10. Kenney, S.C. Regulation of the latent-lytic switch in Epstein-Barr virus / S.C. Kenney, J.E. Mertz // Sem. Cancer Biol. - 2014. - Vol. 26. - P. 60-68.
  11. Kimura, H. Vidarabine therapy for severe chronic active Epstein- Barr virus infection / H. Kimura [et al.] // J. Pediatr. Hematol. Oncol. - 2001. - Vol. 23. - P. 294-299.
  12. Kragsbjerg, P. Chronic active mononucleosis / P. Kragsbjerg // Scand. J. Infect. Dis. - 1997. - Vol. 29, № 5. - P. 517-518.
  13. Kure, S. Inhibition of Epstein-Barr virus infection in vitro by recombinant human interferons alpha and gamma / S. Kure [et al.] // Virus Res. - 1986. - Vol. 5, № 4. - P. 377-390.
  14. Kwok, H. Distribution, persistence and interchange of Epstein- Barr virus strains among PBMC, plasma and saliva of primary infection subjects / H. Kwok [et al.] // P. Los. One. - 2015. - Vol. 10, № 3. - P. 710.
  15. Laichalk, L.L. The dispersal of mucosal memory B cells: evidence from persistent EBV infection / L.L. Laichalk, D. Hochberg, G.J. Babcock // J. Immunity. - 2002. - Vol. 16. - P. 745-754.
  16. Lotz, M. Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus / M. Lotz [et al.] // J. Rheumatol. - 1987. - Vol. 14, № 1. - P. 42-45.
  17. Perry, M. Immunology of the tonsils / M. Perry, A. Whyte // Immunol. - 1998. - Vol. 19, № 9. - P. 414-421.
  18. Sainz, B. Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1 / B. Sainz, W.P. Halford // J. Virol. - 2002. - Vol. 76, № 22. - P. 11541-11550.
  19. Straus, S.E. The chronic mononucleosis syndrome. / S.E. Straus // J. Infect. Dis. - 1988. - Vol. 157, - P. 405-412.
  20. Weng, H.L. Clinical study of anti-hepatic fibrosis effect of IFN- gamma in patients with chronic hepatitis B / H.L. Weng [et al.] // Zhonghua Yi Xue Za Zhi - 2003. - Vol. 83, № 11. - P. 943-947.
  21. Wu, Y.J. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection / Y.J. Wu, W.M. Cai, Q. Li // Hepatobiliary Pancreat. Dis. Int. - 2011. - Vol. 10, № 2. - P. 151-157.

Copyright (c) 2019 Rakityanskaya I.A., Ryabova T.S., Todzhibaev U.A., Kalashnikov A.A., Manuilov A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies